CA-NEXON-AMERICA
25.8.2021 15:02:03 CEST | Business Wire | Press release
Today, Nexon announced that its newest free-to-play mobile RPG KonoSuba: Fantastic Days has reached a whopping one million downloads in just 5 days. Based on the hit comedy anime series streaming on Crunchyroll and HBO Max, the character-collector game is available now on iOS and Android .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005263/en/
Since its initial release and massive success in Japan in February 2020, the worldwide release on August 19, 2021 has already reached the prestigious milestone of one million downloads, with user numbers growing by the day. Players have been enjoying the chance to adventure into the fantasy world of KonoSuba , and positive response from fans has been a big factor in its rapid success.
To celebrate one million downloads, Nexon will be rewarding all players who log into KonoSuba: Fantastic Days with the following free currency gift and limited time event:
- Reward : 1,500 Free Quartz for players who log in from 5:00 pm PDT August 30 to 8:00 am PDT September 5 (Redeemable once per account)
- Event : Main Quest (Normal) 2x Item Drop from 1:00 am PDT August 31 to 12:59 am PDT September 3
KonoSuba: Fantastic Days features fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness. The characters are voiced by their original Japanese voice actors, including Jun Fukushima, Sora Amamiya, Rie Takahashi and Ai Kayano. Following an original storyline, bespoke new characters have also been created exclusively for the mobile RPG. Published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap, KonoSuba: Fantastic Days is available now on iOS and Android .
Stay up to date about new characters, events by following KonoSuba: Fantastic Days ’ Twitter @playkonosuba and by visiting the official website !
Assets : Press Assets
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World! ”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005263/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom